| scholarly article | Q13442814 |
| P2093 | author name string | Qing Zhou | |
| Zhi Xie | |||
| Xiao Xu | |||
| Chong-Rui Xu | |||
| Yi-Long Wu | |||
| Wei Tang | |||
| Zhou Zhang | |||
| Zhi-Hong Chen | |||
| Jian Su | |||
| Jin-Ji Yang | |||
| Xu-Chao Zhang | |||
| Hong-Hong Yan | |||
| Feng Roger Luo | |||
| Xiao-Yan Bai | |||
| Wen-Feng Li | |||
| Shao-Kun Chuai | |||
| Bin Gan | |||
| Yi-Chen Zhang | |||
| Han Han-Zhang | |||
| Jun-Yi Ye | |||
| P2860 | cites work | Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 |
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer | Q27853013 | ||
| Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. | Q27853162 | ||
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 | ||
| Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. | Q37000646 | ||
| Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer | Q38607259 | ||
| AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients | Q38733979 | ||
| Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor | Q38880070 | ||
| Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. | Q40479490 | ||
| Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study | Q46585165 | ||
| Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study | Q47777525 | ||
| Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. | Q48020812 | ||
| Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. | Q49643911 | ||
| First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. | Q52601362 | ||
| Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. | Q52639687 | ||
| Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. | Q52673333 | ||
| Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance. | Q53734623 | ||
| A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay. | Q53789730 | ||
| Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. | Q54119662 | ||
| Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor | Q57134703 | ||
| Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma | Q58082706 | ||
| GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma | Q89215336 | ||
| Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib | Q90727978 | ||
| Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC | Q91517934 | ||
| Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion | Q91783496 | ||
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 180-187 | |
| P577 | publication date | 2019-04-23 | |
| P1433 | published in | EBioMedicine | Q24912341 |
| P1476 | title | Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. | |
| P478 | volume | 43 |
| Q92680527 | Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib |
| Q90628678 | Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer |
| Q96033773 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised tria |
Search more.